Supplementary Table 1. Univariable hazard ratios for biochemical progression-free survival (bPFS) for all tested covariates

Covariate	Level	n	bPFS (years)	
			Hazard ratio (95% CI)	HR p-value
Race	African American/other	76	2.17 (0.79-5.98)	0.134
	White	125	–	–
Androgen deprivation therapy	No	123	1.05 (0.38-2.90)	0.921
	Yes	78	–	–
PSA	≥ 10	40	3.51 (1.29-9.52)	0.014
	< 10	161	–	–
Pre-treatment MRI	Yes	122	2.64 (0.87-8.02)	0.086
	No	79	–	–
Pre-treatment CT scan	Yes	33	0.36 (0.05-2.70)	0.319
	No	168	–	–
Pre-treatment bone scan	Yes	115	0.79 (0.29-2.11)	0.632
	No	86	–	–
Obese	Yes	39	0.80 (0.23-2.78)	0.725
	No	56	–	–
Insurance	Private	106	1.37 (0.49-3.87)	0.547
	Other/unknown	17	1.19 (0.14-10.02)	0.871
	Medicare	78	–	–
T stage	T1	132	0.60 (0.23-1.61%)	0.314
	T2	68	–	–
Gleason score	3+4	106	0.59 (0.22-1.58)	0.291
	4+3	95	–	–
Supplemental external radiation therapy	No	21	3.76 (0.76-18.62)	0.105
	Yes	180	–	–
Supplemental external radiation therapy target	Prostate + SV	121	0.25 (0.06-1.00)	0.050
	Pelvis	28	0.18 (0.03-1.04)	0.055
	No sEBRT	21	–	–
Percent of cores positive	≥ 50%	57	0.66 (0.09-4.72)	0.680
	< 50%	31	–	–
Age	Not applicable	200	0.98 (0.92-1.04)	0.477
BMI	Not applicable	95	1.02 (0.95-1.09)	0.625